University of Southern California

Research

PAR-20-175: Institutional Development Award (IDeA) Networks for Clinical and Translational Research (IDeA-CTR) (U54 Clinical Trial Optional)

Slots:                                        1

Internal Deadline:                      June 12, 2020

LOI Deadline:                            30 days prior to the application due date

External Deadline:                     October 7, 2020

Award Information:                   Type: Cooperative Agreement

Estimated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Anticipated Amount: The application may request up to $4,000,000 per year in total costs.  This FOA provides an additional one-time cost of up to $300,000 in direct costs in year one for Alterations and Renovations.

Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://research.usc.edu/usc-grants/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.

(2) CV – (5 pages maximum)

Link:               https://grants.nih.gov/grants/guide/pa-files/PAR-20-175.html

Who May Serve as PI:                The PD(s)/PI(s) must hold a senior-level faculty appointment at the applicant institution at the time of application.  The PD(s)/PI(s) must be an established clinical scientist with on-going research program supported by extramural funding. The PD(s)/PI(s) of COBRE and INBRE awards are not eligible.

Purpose:                                   NIH established the Institutional Development Award (IDeA) Program in 1993 to enhance biomedical research activities in states that have had historically low NIH grant funding success rates. The program currently supports competitive research in 23 states and Puerto Rico.  Strengthening clinical and translational research in IDeA-eligible states/jurisdictions is a pressing need, since health conditions such as obesity, diabetes, cardiovascular diseases, cancer, infectious diseases, chronic obstructive pulmonary diseases, maternal health, and substance overuse disorders are disproportionally prevalent in these mostly rural and often economically disadvantaged states/jurisdictions. NIH is committed to supporting health and health research professionals with first-hand knowledge about these challenges to lead the charge in improving the health of residents in IDeA states/jurisdictions.  This funding opportunity announcement (FOA) supports the development and/or enhancement of statewide and/or interstate regional networks for clinical and translational research in IDeA-eligible states/jurisdictions.

The objectives of the IDeA-CTR initiative are the following:

          • To support the development and/or enhancement of infrastructure and human resources required to address clinical and translational research needs in IDeA-eligible states.
          • To strengthen clinical and translational research that addresses the broad spectrum of health challenges faced by populations in IDeA-eligible states/jurisdictions.
          • To foster and coordinate collaboration in clinical and translational research within an IDeA-CTR network and with other institutions.

For the purposes of this initiative, the following definitions apply:

          • “Clinical research” comprises studies and trials in human subjects as defined by NIH Regulations and Policies (https://grants.nih.gov/grants/glossary.htm#ClinicalResearch).
          • “Translational research” includes research that aims to convert basic research advances to practical applications in humans, and research aimed at the adoption of best practices in community healthcare.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.